Latest News about GILD
Recent news which mentions GILD
XBB.1.5, which makes up 28% of new COVID cases in the U.S., fuels worries about a winter wave
January 06, 2023
From MarketWatch
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
January 02, 2023
From Motley Fool
From Benzinga
New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
December 30, 2022
From Benzinga
This New Drug Could Be Gilead Sciences' Growth Catalyst
December 29, 2022
Tickers
GILD
From Motley Fool
3 High-Yielding Dividend Stocks That Could See Hikes in January
December 29, 2022
From Motley Fool
From Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
December 28, 2022
From InvestorPlace
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors' Attention Today
December 27, 2022
From Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
December 27, 2022
Tickers
GILD
From Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
3 Stocks That Could Soar in a Santa Claus Rally
December 25, 2022
From Motley Fool
3 Nasdaq Stocks That Are Up 25% in 3 Months
December 23, 2022
From Motley Fool
FDA Approves Gilead's New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients
December 22, 2022
Tickers
GILD
From Benzinga
Ahead of a year of big unknowns, here are two sectors investors should consider, says this money manager
December 22, 2022
From MarketWatch
Gilead Sciences (GILD) Stock Falls on Lung Cancer Drug Data
December 20, 2022
From InvestorPlace
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
From Benzinga
Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients
December 20, 2022
From Benzinga
Beat the Dow Jones With This Unstoppable Dividend Stock
December 12, 2022
From Motley Fool
Why Is Arcellx (ACLX) Stock Up 25% Today?
December 09, 2022
From InvestorPlace
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
December 09, 2022
From Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 15 Years
December 08, 2022
Tickers
GILD
From Benzinga
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
December 08, 2022
From Benzinga
Is Gilead Sciences Stock Still a Buy After Soaring in 2022?
December 08, 2022
Tickers
GILD
From Motley Fool
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.